Aerovate underwent a reverse merger with Jade Biosciences on April 28, 2025, which expanded its operational capacity and platform. The company operates in the pulmonology sector, competing against established players like Gossamer Bio and Corsair Pharma. With a clinical-stage asset and recent merger integration, Aerovate is positioned to advance its lead program through ongoing development.
Cyborg Score Rationale
AV-101 failed in treatment of PAH as of June 2024, creating significant clinical and financial headwinds. However, the company has raised $203M, providing runway for clinical development, and the merger with Jade Biosciences (April 2025) suggests continued investor confidence in the platform.
Top Insights
Lead program AV-101 experienced clinical setback (June 2024), requiring strategic pivot or program reassessment
Recent reverse merger with Jade Biosciences (April 2025) signals integration of complementary assets or capabilities
Pulmonology sector saw $448M in funding in 2026 YTD, indicating broader investor interest in rare lung disease
Stock has traded in $6.57–$28.00 range over past 12 months, reflecting volatility typical of clinical-stage biotech
Named Competitors
Gossamer Bio — Rare pulmonary disease therapeutics
Actelion — Pulmonary hypertension and rare disease drugs